Every AXLRx Plaque Psoriasis report, across 5 report types. Each is scoped to your asset and verified to a live source.
Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US: IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2, and the efficacy bar has moved from PASI 75 to PASI 90.
Psoriasis affects about 3.0% of US adults, roughly 7.55 million people, but only the moderate-to-severe minority reaches the systemic and biologic therapies that define the commercial market.
US access to plaque psoriasis biologics is gated by step therapy and reshaped by two forces landing together: Inflation Reduction Act price negotiation on Stelara and Enbrel, and biosimilar erosion of adalimumab and ustekinumab.
Bimekizumab already clears PASI 90 in 85% of patients at week 16. A new plaque psoriasis entrant has to win on dosing interval or route, not incremental clearance, against an incumbent price anchor the IRA has already cut 66-67%.
Stelara's negotiated price falls to $4,695 from a $13,836 list, a 66% cut, effective January 2026, the same month ustekinumab biosimilars begin launching. Two separate pricing shocks land on one legacy biologic at once.
AXLRx publishes Competitive Intelligence, Disease Landscape, Payer & HTA, Launch Readiness, and Pricing Strategy Model for Plaque Psoriasis. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Plaque Psoriasis coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Plaque Psoriasis reports were updated July 2026.